The Top ASX Health Stocks for 2025: Here Are Our 5 Picks!

Here Are Our 5 Top ASX Health Stocks for 2025!

Avita Medical (ASX:AVH)

OK, first thing’s first. We know this ASX health stock fell 14% on January 8 after it announced a revenue downgrade for Q4. But the past is the past. The company told investors to expect $100-106m revenue in CY25, 55-65% above CY24. Inevitably, this is expected to come from 2 products that were just approved prior to Christmas.

One is Recell Go Mini, that can treat even smaller areas that its existing technology. The other is Cohealyx, its new collagen-based dermal matrix. This ensures that Avita can meet skin defects at literally every layer, ensuring that wounds can be closed in a better was than stitches.

We reiterate our view that Avita’s FDA approvals are game-changing for the company, opening up a much larger market than what it had before. This could be one of the best performing biotech stocks of 2025, if all goes to plan.

Opthea (ASX:OPT)

Opthea is developing a drug called Sozinibercept (formerly known as OPT-302) that targets wet AMD, the world’s leading cause of blindness. More than five years after successful Phase 2 results, it expects to report Phase III results in the first half of next year. The company is running 2 trials with nearly 1,000 subjects in each – results from the first trial are expected in the March quarter of 2025, while the second is due in the June quarter.

The company is targeting a 5.7 letter change in BCVA from baseline at 24 weeks – essentially how many more letters can a patient read on that typical letter chart you read at your eye check ups. Success here could lead to the company seeking FDA approval, not to mention a share price re-rate on the ASX. 

Dimerix (ASX:DXB)

Dimerix is in the middle of a Phase III trial or its DMX-200 drug for a condition known as Focal Segmental Glomerulosclerosis (FSGS). For patients with FSGS, the kidneys’ ability to purify (clean) the blood is impaired. This can lead to kidney failure that may eventually requires dialysis or a kidney transplant.

Results from Part 1 of the trial, released in April 2024, showed positive results and paved the way to the next part of the trial. The outcome of the second interim analysis is expected by mid-CY25 and will be very crucial – being expected to generate sufficient evidence to support conditional marketing approval

There could be other catalysts beforehand, including potential licensing deals for the US and China which are bigger markets than any the company has licensed to data.

CSL (ASX:CSL)

Let’s turn out attention to the largest ASX healthcare stock. The company anticipates its profit to be $3.2-3.3bn for FY25 and for revenues to be 5-7% higher. It has proven itself to be a long-term stable investment over time. We expect interest rate cuts in the US to improve margins in its blood plasma business. Another catalyst could from HEMGENIX, the first ever FDA-approved gene therapy for hemophilia B, that is one of the world’s most expensive drugs, costing US$3.5m.

Blinklab (ASX:BB1)

BlinkLab has an e-platform (BlinkLab Dx 1) that can help diagnose neurological disorders in children such as ADHD and autism. Yes, a formal diagnosis as opposed to a general subjective judgement. The test makes a judgement by biomarker detections, evaluating brain function, computer vision and facial reflexes in response to visual and auditory stimuli.

2025 is expected to be the year that this company starts a large-scale clinical trial that could be the key to getting BlinkLab Dx 1 approved in the USA. It will take more than a year to complete, but we could see interim data before this calendar year is out.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips